Imogam Rabies-Ht
Need help?
Our patient support team is available Monday through Friday 8AM - 6PM PST, and Saturday 9AM - 12PM PST.
What Is Imogam Rabies-Ht?
Imogam Rabies-Ht is a prescription medication classified as an immune serum. It is produced by Sanofi Pasteur, a pharmaceutical company. This medication is specifically used for post-exposure prophylaxis against the rabies virus. Rabies is a serious viral infection that affects the central nervous system and is usually transmitted through the bite or scratch of an infected animal. Imogam Rabies-Ht contains antibodies that help the body fight against the rabies virus and prevent its spread. Imogam Rabies-Ht is typically administered in conjunction with the rabies vaccine to provide immediate protection while the vaccine stimulates the body's own immune response. It is important to receive prompt medical attention if there is a risk of rabies exposure, as early treatment can be life-saving. As with any medication, Imogam Rabies-Ht may cause side effects such as redness, swelling, or pain at the injection site. Serious allergic reactions are rare but possible, and immediate medical attention should be sought if any signs of an allergic reaction occur. It is crucial to follow the dosage and administration instructions provided by a healthcare professional to ensure the effectiveness and safety of this medication.
How to use Imogam Rabies-Ht?
Imogam Rabies-HT is a prescription medicine that belongs to the immune serums class. It is primarily used for the prevention and treatment of rabies, a viral infection that affects the central nervous system. This medication is administered through an injection, and the dosing regimen may vary depending on factors such as the individual's age, weight, and the specific situation (e.g., pre-exposure prophylaxis or post-exposure prophylaxis). When used for pre-exposure prophylaxis, Imogam Rabies-HT is typically administered in combination with a rabies vaccine. The injections are given on specific days over a period of time, as determined by a healthcare professional. This helps to build immunity against the rabies virus. In cases of post-exposure prophylaxis, Imogam Rabies-HT is usually given as soon as possible after a potential exposure to rabies. The initial dose is typically higher, followed by additional doses over a specified period of time, again as recommended by a healthcare professional. It's important to follow the instructions provided by your healthcare provider and complete the full course of treatment as prescribed. This will help ensure the effectiveness of the medication in preventing or treating rabies. If you have any questions or concerns about the usage of Imogam Rabies-HT, it is best to consult with your healthcare provider for personalized guidance.
Imogam Rabies-HT is a prescription medication belonging to the class of immune serums. It is used for the prevention of rabies infection in individuals who have potentially been exposed to the virus. There are several important warnings associated with the use of Imogam Rabies-HT that patients and healthcare providers should be aware of. These include: 1. Allergic reactions: Imogam Rabies-HT is made from human blood plasma and may contain small amounts of immunoglobulin E (IgE), which can cause allergic reactions in some individuals. It is important to inform your healthcare provider if you have a history of allergies, especially to human immune globulin or other blood products. 2. Previous adverse reactions: If you have received immunoglobulin-based products in the past and experienced any adverse reactions, such as a severe allergic reaction or thrombosis, you should discuss this with your healthcare provider before using Imogam Rabies-HT. 3. Injection site reactions: Imogam Rabies-HT is typically administered by injection into the muscle or subcutaneously. Injection site reactions, such as pain, redness, swelling, or itching, may occur. If you experience any persistent or worsening reaction, contact your healthcare provider. 4. Interference with vaccine response: Imogam Rabies-HT may interfere with the development of an immune response to live virus vaccines. If you require a live virus vaccine, such as measles, mumps, rubella (MMR), or varicella (chickenpox), inform your healthcare provider of your recent Imogam Rabies-HT use. 5. Transmission of infectious agents: As Imogam Rabies-HT is derived from human plasma, it may carry a risk of transmitting infectious agents, although thorough screening and testing of plasma donors is conducted. The risk is considered low but cannot be completely eliminated. It is important to discuss these warnings, along with any potential benefits and risks, with your healthcare provider before starting treatment with Imogam Rabies-HT. They will be able to provide personalized advice based on your specific circumstances.
Before taking Imogam Rabies-HT, there are several important warnings and precautions that you should be aware of. Here are some key points to consider: 1. Allergies: Inform your healthcare provider if you have a history of allergies or hypersensitivity to any components of Imogam Rabies-HT. This medication contains human plasma proteins, and allergic reactions are possible. 2. Immunoglobulin A (IgA) deficiency: If you have IgA deficiency, it's crucial to inform your healthcare provider. Imogam Rabies-HT contains small amounts of IgA, which could potentially cause an allergic reaction in individuals with this deficiency. 3. Bleeding disorders: If you have a known bleeding disorder or are taking medications that affect blood clotting, inform your healthcare provider before receiving Imogam Rabies-HT. This medication may increase the risk of bleeding or bruising. 4. Interference with vaccine response: Imogam Rabies-HT may interfere with the immune response to live attenuated virus vaccines, such as measles, mumps, rubella, and varicella. It's essential to discuss with your healthcare provider if you are scheduled to receive any vaccines. 5. Transmission of infectious agents: Like all blood-derived products, there is a risk of transmitting infectious agents with Imogam Rabies-HT. The manufacturer has implemented several measures to reduce this risk, but it's important to be aware of the possibility. It is crucial to consult with your healthcare provider to discuss your medical history and any potential risks or concerns before taking Imogam Rabies-HT. They will be able to assess your individual situation and provide appropriate guidance.
Imogam Rabies-HT is a prescription medication belonging to the Immune Serums class. It is used for the prevention of rabies in individuals who have been exposed to the virus. This medication works by providing passive immunity, meaning it contains antibodies that help the body fight against the rabies virus until the person's immune system develops its own protection. As with any medication, Imogam Rabies-HT can cause side effects. Common side effects may include pain, swelling, or redness at the injection site. Some individuals may also experience fever, headache, dizziness, or nausea. These side effects are usually mild and subside on their own. Serious allergic reactions to the medication are rare but can occur. Signs of an allergic reaction may include difficulty breathing, hives, swelling of the face or throat, or a rapid heartbeat. If any of these symptoms develop, immediate medical attention should be sought. It's important to discuss any concerns or potential side effects with your healthcare provider before starting this medication. They can provide you with more detailed information and address any specific concerns you may have.
Imogam Rabies-HT is an immune serum used for post-exposure prophylaxis against rabies, a potentially deadly viral infection. It is produced by SANOFI PASTEUR, a pharmaceutical company specializing in vaccines and biological products. The active ingredient in Imogam Rabies-HT is human rabies immune globulin (HRIG). HRIG is made from a pool of plasma collected from individuals who have been immunized against rabies. This plasma contains antibodies that can neutralize the rabies virus and provide immediate protection against the infection. In addition to HRIG, Imogam Rabies-HT may also contain inactive ingredients such as stabilizers, preservatives, and albumin (a protein that helps maintain the stability of the product). It is important to note that Imogam Rabies-HT should be administered along with a series of rabies vaccine doses to provide full protection against rabies. This treatment should be initiated as soon as possible after exposure to the virus, typically within 24 hours. As always, please consult with a healthcare professional for further information and guidance regarding this medication.
Imogam Rabies-HT, which is an immune serum used for the prevention of rabies, should be stored and handled appropriately to maintain its efficacy and safety. Here are the recommended guidelines for storage: 1. Temperature: Imogam Rabies-HT should be stored in a refrigerator between 2°C and 8°C (36°F and 46°F). It is essential to maintain a consistent temperature within this range to ensure the stability of the medication. 2. Protection from light: The medication should be protected from exposure to direct sunlight or artificial light sources. Keeping it in its original packaging or a light-resistant container can help prevent degradation caused by light exposure. 3. Avoid freezing: Imogam Rabies-HT should not be frozen. Freezing can cause the medication to lose its effectiveness and may alter its properties. Therefore, it is crucial to store it at a temperature above freezing at all times. 4. Proper sealing: Ensure that the vial or container is tightly closed after each use. This helps to prevent contamination and maintain the integrity of the immune serum. 5. Check expiration date: Always check the expiration date before using Imogam Rabies-HT. Expired medication should be discarded properly and not used, as it may have reduced effectiveness or potential harm. It is important to follow these storage guidelines to ensure the medication's potency and safety. If you have any specific questions or concerns about storage or handling, it is best to consult with a healthcare provider or pharmacist for further guidance.